[Nephrolithiasis within the framework of internal medicine (author's transl)].
D000970:Antineoplastic Agents / Q000009:adverse effects; D003553:Cystine / Q000378:metabolism; D006073:Gout / Q000150:complications; D006801:Humans; D007669:Kidney Calculi / Q000139:chemically induced / Q000209:etiology* / Q000378:metabolism; D007926:Lesch-Nyhan Syndrome / Q000150:complications; D009196:Myeloproliferative Disorders / Q000150:complications; D009748:Nutrition Disorders / Q000150:complications; D013789:Thalassemia / Q000150:complications; D014527:Uric Acid / Q000378:metabolism; D014528:Uricosuric Agents / Q000009:adverse effects; D014970:Xanthines / Q000378:metabolism
D000970:Antineoplastic Agents; D014528:Uricosuric Agents; D014970:Xanthines; D014527:Uric Acid; D003553:Cystine
Die Nephrolithiasis im Rahmen der Inneren Medizin.